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4D dose calculationa b s t r a c t
Purpose: Respiratory impacts in pencil beam scanned proton therapy (PBS-PT) are accounted by exten-
sive 4D dose calculations, where deformable image registration (DIR) is necessary for estimating defor-
mation vector fields (DVFs). We aim here to evaluate the dosimetric errors induced by different DIR
algorithms in their resulting 4D dose calculations by using ground truth(GT)-DVFs from 4DMRI.
Materials and methods: Six DIR methods: ANACONDA, Morfeus, B-splines, Demons, CT Deformable, and
Total Variation, were respectively applied to nine 4DCT-MRI liver data sets. The derived DVFs were then
used as input for 4D dose calculation. The DIR induced dosimetric error was assessed by individually
comparing the resultant 4D dose distributions to those obtained with GT-DVFs. Both single-/three-field
plans and single/rescanned strategies were investigated.
Results: Differences in 4D dose distributions among different DIR algorithms, and compared to the results
using GT-DVFs, were pronounced. Up to 40 % of clinically relevant dose calculation points showed dose
differences of 10 % or more between the GT. Differences in V95(CTV) reached up to 11.34 ± 12.57 %. The
dosimetric errors became in general less substantial when applying multiple-field plans or using rescan-
ning.
Conclusion: Intrinsic geometric errors by DIR can influence the clinical evaluation of liver 4D PBS-PT
plans. We recommend the use of an error bar for correctly interpreting individual 4D dose distributions.
 2018 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 128 (2018) 174–181 This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).When treating moving targets in the thorax or abdomen with
pencil beam scanned proton therapy (PBS-PT), due to the presence
of breathing motion, a time-resolved 3D (4D) image is necessary
for quantifying the motion characteristics and performing a 4D
dose calculation. For treating this type of tumour with a highly pre-
cise technique such as PBS-PT, a 4D dose calculation is crucial in
order to take into account the deterioration of the dose distribution
due to the relative motion between the target and the delivered
pencil beams (interplay effects) [1–3].
To calculate motion induced geometric differences between
two image phases, deformable image registration (DIR) is the stan-
dard approach for building up a point-to-point correlation between
corresponding features. To perform DIR, a fixed and a moving
image are pre-defined to estimate the patient’s deformable motion
between these two images [4]. The result of DIR is a deformationvector field (DVF), which contains vectors for each voxel pointing
from the fixed image towards the moving image.
For any form of radiotherapy, DIR is one of the irreplaceable
components for both inter- and intra- fractional dosimetric evalu-
ation. It is especially important for PBS-PT, due to its high sensitiv-
ity to geometric accuracy. However, it is well known that DIR is an
ill-posed problem intrinsically [5]. When applying different DIR
methods to the same image pair, the resulting motion estimations
can be inaccurate and differ significantly from each other [6]. Some
of these errors are quantifiable, and can be calculated by compar-
ing the DIR estimated motion of well-defined landmarks to their
actual positions in both images (the so-called ground truth (GT)
data). This is the classic approach of evaluating any DIR algorithm
performance, as used by many previous publications [7,8]. Despite
compromising the efficiency for the error quantification, the more
landmarks that are defined, the more reliable the results will be. In
contrast, there are also unquantifiable errors in featureless regions
of the images, where the deformable problem is intrinsically ill-
defined. Motion vectors in these regions will directly depend on
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rithm, and it is therefore unavoidable that ambiguity between dif-
ferent algorithms will exist.
Any form of registration uncertainty can directly lead to distin-
guishable differences in dose distributions, which consequently
influence any further dosimetric analysis and clinical decision-
making [9]. In the literature, a number of studies have investigated
the dosimetric uncertainties induced by a particular DIR method
[10,11]. However, their conclusions were restricted to their
selected DIR method, and a consensus on the clinical impact of
DIR uncertainty is still difficult to achieve. Yeo et al. [12] compared
calculated doses based on results from several available DIR algo-
rithms with a measured dose using a deformable 3D dosimeter.
However, DIR errors for real patient geometries may perform dif-
ferently in contrast to the rather simple experimental setup used
in that work.
Zhang et al. [6] showed that the ambiguity of two DIR
approaches can lead to significant differences in the estimated
motion maps, and subsequent 4D dose distributions, among liver
cancer patients for PBS-PT, even if landmark registration errors
were similar. Due to the lack of a comprehensive GT-DVF however,
it is often impossible to validate the accuracy of DIR in the whole
region of interest.
In this work, we would like to improve the above studies in two
aspects. First, to investigate the systematic errors induced by DIRs
in 4D dose calculations, using the unique advantage of comprehen-
sive GT-DVFs extracted from synthetic 4DCT-MRI [13]. Second, we
include multiple DIR methods to reveal the extent of potential vari-
ation induced by different algorithms. As such, six DIR methods
(five commercially available and one research version) have been
applied to nine 4DCT-MRI data sets to estimate deformable motion
within the abdomen region. Compared to previous works, we also
consider comprehensive GT-DVFs as reference to quantify the
absolute accuracy for deformable motion estimation. Conse-
quently, the resulting 4D dose distributions generated using differ-
ent DIR algorithms can be directly compared under conditions of
varying plan configurations, rescanning scenarios, patient geome-
tries, and motion scenarios.Materials and methods
Synthetic 4DCT-MRI and ground truth deformation vector fields
(GT-DVFs)
4DCT-MRI data sets consist of end-of-exhalation 3DCTs (refer-
ence phases) modulated by consecutive and extended breathing
motion extracted from 4DMRI data through a validated image pro-
cessing method [13–15] (Fig. 1, upper left). Through this process,
synthetic 4DCT-MRI data sets within the liver are obtained by
warping the reference phase with DVFs extracted from 4DMRI
using a combination of multiresolution affine registration and B-
spline non-rigid registration [15].
Nine such 4DCT-MRI data sets, generated from motion artefact-
free 3DCTs of three liver cancer patients (denoted as PI, PII, and PIII
respectively), were included in this study. The reference phases of
the three patients were modulated by three different 4DMRI
motion scenarios indicated as motions A, B, and C [16]. Clinical tar-
get volumes (CTVs) at the reference phase were 122, 264, and 403
cm3 for patients I, II, and III respectively. Only 4DCT-MRI data sets
corresponding to the first breathing cycle were analysed, and no
consideration of motion irregularity has been included in the
study. For the nine data sets, the amplitude for the first breathing
cycle (given by the mean of the amplitude of all different points
within the whole liver region) of motion scenarios A, B, and C were
7.82 (SD = 2.01), 20.61 (SD = 3.39), and 16.88 (SD = 2.78) mm
respectively. Additionally, motion periods (extracted using Fourieranalysis) for this first cycle equalled 3.66, 4.62, and 7.22 s for A, B,
and C respectively. The corresponding DVFs extracted from 4DMRI
to generate these nine 4DCT-MRI data sets were then defined as
the GT-DVFs. Subsequently, new DVFs were extracted from these
nine 4DCT-MRI data sets using the different DIR methods being
investigated (see Fig. 1). These GT-DVFs and DIR estimated DVFs
were used for the 4D dose calculation analysis.Deformable image registration (DIR) methods and derived deformation
vector fields (DVFs)
Six DIR methods have been included in this study. DIR1 and
DIR2 are available in the RayStation (RaySearch Laboratories,
Stockholm, Sweden) treatment planning system used in the UMCG,
whereas DIR3 and DIR4 [6] are algorithms provided in open source
software (Plastimatch; www.plastimatch.com) and used at PSI.
DIR5 and DIR6 were developed in turn by the commercial medical
imaging software company Mirada Medical (Oxford, UK) and by
the Computer Vision Laboratory in ETH Zurich (Zurich, Switzer-
land) respectively. The different DIR methods are based on the
ANACONDA [17], Morfeus [18,19], B-splines, Demons, CT Deform-
able [20,21], and Total Variation [22] algorithm respectively
(Suppl. 1). For each data set, all six approaches were applied to
the reference phase as the fixed image. The remaining phases were
defined as successive moving images (see Table S.1).4D dose calculation
The DVFs resulting from the application of the six DIR methods
were used as input to the in-house 4D dose calculation engine at
PSI, which is an extension of the 3D dose calculation algorithm.
The gantry (beam) coordinate system is defined as ðs; t; uÞ, in
which s is the pencil beam central axis direction and ðt0;u0Þ its
position orthogonal to the field direction (Fig. 2(a)). The clinically
used dose grid size in this coordinate system is 4  4  2.5 mm3.
To extend the 3D dose calculation to a 4D dose calculation,
time-dependent displacements of dose grid points for motions in
the t and u directions are taken into account using displacement
and density-variation maps derived from each phase of the rele-
vant 4DCT-MRI data. The 4D dose calculation algorithm first esti-
mates the time stamp of each delivered pencil beam [13]. The
DIR extracted DVFs are then geometrically translated and rotated
into the gantry ðs; t; uÞ coordinate system, and sampled by the
dose grid size to provide displacement maps for each dose grid
point [6]. Density-variation maps are derived from the different
4DCT-MRI phases using Siddon’s algorithm [23]. With these dis-
placement and density-variation maps, the offsets of the dose grid
points from their nominal positions are calculated and a 4D dose
distribution obtained.4D planning configurations
Static, single-field uniform dose (SFUD) plans [24] were calcu-
lated on each of the reference phases of the three patients. Both
single- and three-field plans were investigated. Field arrangements
were anterior-posterior (F1), right lateral (F2), and anterior-inferior
oblique (F3), with the three-field plan being a combination of all
fields. 4D dose distributions for these were then subsequently
obtained by using either the GT-DVFs or the DVFs resulting from
the six DIR methods in the 4D dose calculation algorithm (Fig. 1).
Single scan or five times layered rescanning [16] were simulated
with the scanning parameters of Gantry 2 at PSI [25–27]. Plan
delivery started at the reference phase of the corresponding
4DCT-MRI. All analysed plan configurations and respective
notations are given in Suppl. 2.
Fig. 1. Schematic representation of the workflow adopted in this paper.
Fig. 2. (a) Gantry (or beam) coordinate system defined by ðs; t; uÞ represented in blue. (b) Anterior-posterior (F1) fVOI of patient PIII (in purple) for the corresponding
geometric field-specific registration error quantification.
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The impact of using the different DVFs derived from the
applied DIR methods in the 4D dose calculation has been
assessed by (1) quantifying the geometric error in the beam coor-
dinate system and (2) analysing dosimetric errors in the 4D dose
distribution.
The DIR induced geometric error was quantified by the absolute
differences of the derived DVFs from each DIR method with respect
to the GT-DVFs (Suppl. 3). Since this study is focused on the impact
of DIR on 4D dose distributions, the assessment of the geometric
error was performed in the field direction, by analysing the t and
u coordinates within a defined field-specific volume of interest
(fVOI) (Fig. 2(b)). To more precisely correlate the geometric error
to the dosimetric error, we defined the fVOI as the dose region
where the dose calculation grid covers patient geometry (to
exclude dose regions outside the patient). As such, the geometric
evaluation was performed only in regions that directly contribute
to the 4D dose calculation.The 4D dose distributions obtained from the DVFs derived from
the six DIRs were individually calculated and compared to those
resulting when using the GT-DVFs. Both dose-volume histograms
(DVHs) with error bands, as well as V95(CTV) values were analysed
to quantify the impact of DIR in clinical practice. Difference DVHs
(DDVHs), which correspond to the histograms of the absolute dose
difference between the individual DIR estimated and GT 4D plans
in an extension of the CTV volume (CTV + 1 cm), were computed.
Finally, for each investigated DIR method, percentages of the
extended CTV volume with absolute dose differences higher than
10 % were extracted from the DDVH for analysis.Results
DIR induced geometric error
Geometric registration errors with respect to motion scenarios
and DIR methods for all single-field arrangements are given in
Table 1
Field-specific geometric errors before and after DIR for the analysed configurations: three different single-field directions and three liver cancer patients, each modulated by
motion scenarios A, B, or C.
Motion Before DIR After DIR
(mean ± SD) [mm] (mean ± SD) [mm]
GT DIR1 DIR2 DIR3 DIR4 DIR5 DIR6 Averaged
A 1.47 ± 0.26 1.05 ± 0.29 1.01 ± 0.15 1.04 ± 0.23 0.76 ± 0.15 0.74 ± 0.17 0.72 ± 0.16 0.89 ± 0.06
B 3.91 ± 0.57 2.44 ± 0.88 2.34 ± 0.33 2.76 ± 0.56 1.97 ± 0.46 1.93 ± 0.52 1.85 ± 0.55 2.22 ± 0.18
C 4.47 ± 0.57 2.84 ± 0.52 2.66 ± 0.35 3.21 ± 0.54 2.38 ± 0.35 2.34 ± 0.38 2.22 ± 0.42 2.61 ± 0.08
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for the smallest motion cases (motion scenario A) were achieved
by DIR6 and DIR1 (0.72 ± 0.16 mm and 1.05 ± 0.29 mm respec-
tively). Despite motion B having the highest amplitude within
the liver (Suppl. 4.1), motion C actually showed larger movement
in the different single-field directions within the selected fVOI.
For motion C, all the errors increased up to 3.21 ± 0.54 mm for
DIR3, 2.84 ± 0.52 mm for DIR1, and 2.22 ± 0.42 mm for DIR6. Over-
all, the best performance was achieved by DIR6 for all three motion
scenarios. Most importantly, it was also observed that all DIR
methods underestimated the GT motion amplitudes (Table S.4.1).DIR induced dosimetric error
Without rescanning, pronounced differences in 4D dose distri-
butions were observed among the different DIR scenarios, and in
comparison to the GT generated 4D dose distributions (Fig. 3(a)).
Indeed, the impact of interplay was clearly different when using
different DVFs as input to the 4D dose calculation. For the GT,
DIR2, DIR4, DIR5, and DIR6 the effects of interplay were more pro-
nounced than for the other two methods (DIR1 and DIR3), in which
the dose distributions look more homogeneous. In fact, for this par-
ticular 4D plan configuration, DVHs of the CTV and DDVHs of the
extended CTV volume, obtained from the six DIR 4D plans, clearly
differed from the GT DVH (Fig. 3(b.i) and (b.ii)), with all DIR plans
underestimating the dose in-homogeneity due to the interplay
effects in comparison to the GT plan. Additionally, substantial
absolute V95(CTV) differences (between the GT and all investigated
DIR methods) were observed (Fig. 4). For motion A, and single
fields with single scans, V95(CTV) differences of 7.91 ± 3.46 % were
observed for DIR3, and 2.02 ± 1.28 % for DIR2. Moderate motions in
the fVOI (motion scenario B) and single fields without rescanning
showed the greatest differences, with DIR3 and DIR2 having differ-
ences of 10.58 ± 14.08 % and 1.43 ± 1.37 % respectively. Of the six
tested DIR methods, DIR2 achieved the lowest errors in V95(CTV)
for most situations with the best prediction of interplay effects in
comparison to the GT.
Rescanning and/or multiple-field plans smoothed out the
V95(CTV) differences for all three motion scenarios. For instance,
for motion scenario B, three-field plans with rescanning resulted
in absolute V95(CTV) differences to the GT of 3.46 ± 1.40 % and
0.23 ± 0.19 % for DIR3 and DIR2 respectively. For the smallest
motion, negligible dosimetric errors were obtained for all DIR
methods (0.37 ± 0.38 % for DIR3, 0.30 ± 0.17 % for DIR2, and 0.24
± 0.18 % for DIR4). V95(CTV) values for all 4D plan configurations
can be found in Table S.4.2, showing that overestimation of target
coverage is consistent for the single-field single/rescanned, or
multiple-field single scan DIR generated plans.
DDVH bands in the extended CTV for all 4D plan configurations
(as a function of DIR for each motion scenario (Figs. S.4.2.1 and
S.4.2.2)) show that the accuracy of a particular DIR method does
not depend just on the motion characteristics, or that any single
DIR algorithm performed better for one particular motion scenario.
Generally however, dose differences between DIR2 and the GT
were the smallest for most of the 4D plan configurations and forall analysed motion scenarios. For the others, up to 40 % of the vol-
ume of extended CTV had absolute dose differences in comparison
to the GT of more than 10 % for single-field plans delivered with a
single scan (Fig. 5(a)). The largest dosimetric differences occurred
for single-field plans delivered with a single scan for the largest
motions (B and C). Dose differences using all DIRs could however
be smoothed out when applying rescanning or adding fields to
the treatment plan (Fig. 5(b)).Discussion
We have shown in this study that the application of different
DIR methods to extract motion from 4D data sets can result in pro-
nounced differences. Geometric differences of up to 1.05 ± 0.29
mm for the smallest motion amplitude (motion A) and 3.21 ±
0.54 mm for larger motions (motion C) have been observed. With-
out motion mitigation, associated dosimetric differences in target
coverage (assessed as differences in V95(CTV)) were as high as
7.91 ± 3.46 % for motion A and 11.34 ± 12.57 % for motion B. More-
over, up to 40 % of the extended CTV volumes have been predicted
to have absolute dose differences in comparison to the GT dose of
more than 10 %. However, differences in 4D dose distributions
among different DIR scenarios, and compared to the GT, were sig-
nificantly smoothed out in most cases when using multiple-field
treatment plans and/or rescanning [26]. In addition, it was con-
firmed that larger motion amplitudes and deformations contribute
to larger geometric registration errors and consequently larger
dosimetric errors [6]. However, target coverage (quantified by
the V95(CTV)) was highly dependent on other factors, such as mag-
nitude of the interplay effects, and no linear relationship between
target coverage and motion amplitude could be found.
The 4D dose calculation algorithm selected for this project is the
one developed at PSI. It obtains a 4D dose distribution by deform-
ing the dose grid as a function of time, instead of performing mul-
tiple calculations of the dose on different 3DCT phases, which need
to be subsequently warped back to a reference phase for dose accu-
mulation [28–30]. Thus, it has the potential advantage of allowing
for a high number of recalculations in an acceptable time-frame.
Additionally, unlike the more standard 4D algorithm, the 4D dose
calculation of PSI employs linear interpolation for the present
motion between the phases of the 4D imaging and this approach
has been shown to provide more accurate results [14,31,32].
Instead of focusing solely on the assessment of registration
ambiguity as in the work performed by Zhang et al. [6], this study
systematically investigates the performance of a variety of DIR
algorithms, with respect to GT-DVFs, as part of a 4D dose calcula-
tion. Naturally, such GT-DVFs have also been extracted from
4DMRI using DIR and one could argue therefore, that DIR induced
error is already present in these GT-DVFs. As such, these do not
represent ‘real’ GT anatomical motion, but rather an estimation
that will depend on the characteristics of the extraction method
used. Indeed, we cannot deny that DIR induced error is present
in the GTs. However, these are treated as GTs for the 4DCT-MRI
data set itself (where the different DIRs are applied), and not for
Fig. 3. 4D dose calculation results for the example 4D plan configuration of patient geometry PIII modulated by motion scenario C, and treated with the single anterior-
posterior field F1 applied without any rescanning. This corresponds to the patient case with the largest tumour volume and moderate motion amplitude within the liver, but
largest movement in the field direction within the selected fVOI. (a) 4D dose distributions using GT, DIR1, DIR2, DIR3, DIR4, DIR5, and DIR6 DVFs. The white normal and white
dashed lines represent the CTV and CTV + 1 cm (extended CTV) delineations respectively. (b.i) CTV DVH and (b.ii) extended CTV DDVH curves obtained with the six DIR
methods. The black solid line gives the DVH curve calculated with the GT. The red shadow represents the band obtained by using different motion estimation methods, and
the solid red line is showing the mean value from the six DIRs.
178 DIR induced dosimetric error for PBS-PTthe 4DMRI, and so these errors turn out to have minimal impact on
our conclusions. Additionally, due to the much higher contrast in
abdomen MRI images, we believe the DIR errors for the GTs are
rather limited. Therefore, for DIR error assessment applications,
the GT-DVFs used here as reference provide dense image features
for comparison, being a great advantage over the common
approach that relies on the sparse distribution of identifiable land-
marks [7,8]. Moreover, the recently published American Associa-
tion of Physicists in Medicine task group 132 report provided
recommendations for clinical DIR quality assurance, such as a dig-
ital phantom [32].
Although several 4D treatment plan configurations using SFUD
have been analysed, further research still needs to be performed
analysing 4D intensity-modulated proton therapy (IMPT) plan con-
figurations. In addition, statistics could be improved by setting dif-
ferent starting phases for the treatment delivery, and only onebreathing cycle has been considered, which in the 4D dose calcula-
tion was repeated, cycle-to-cycle, over the duration of the full
delivery time per field. Results may vary even more if true, variable
breathing patterns were taken into account. As such, the influence
of irregular breathing patterns, as provided by the 4DCT-MRI
approach, will be exploited in future work.
Interestingly, the geometric and dosimetric accuracies provided
by all tested DIR methods are not directly correlated. For most sit-
uations, Total Variation (DIR6) provided the lowest field-specific
geometric errors and Morfeus (DIR2) the lowest dosimetric errors.
However, it is important to remember the complex nature of 4D
dose calculations, and so multiple other variables could have influ-
enced this lack of correlation. Furthermore, DIR2 is the only algo-
rithm that requires a contour of the liver to be delineated on all
the registered image pairs, indicating that the addition of such
anatomical information to the algorithm is a safe approach to
Fig. 4. Absolute differences between the V95(CTV) of a particular DIR method and the GT V95(CTV) for all analysed 4D plan configurations. These overall V95(CTV) errors are
calculated by the mean ± SD of the individual errors given by all three patient geometries combined, with respect to modulated motion scenario (a) A, (b) B, or (c) C, single- or
three-field plans, and single scan or five times layered rescanning deliveries.
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requires a considerable amount of manual work. Therefore, there
should be careful consideration about which registration method
to choose and whether the additional work is justified. As such,
the choice of a slightly less accurate, but more time efficient, DIR
method can have advantages as long as the uncertainties resulting
from these approaches are understood. Indeed, we would recom-
mend that, given the lack of accuracy demonstrated in this work
between the different DIRs, it would make sense to provide error
bars on dose calculations that depend on such algorithms. Such
error bars could be generated by systematic analysis of dose calcu-
lations using different DIR algorithms for different treatment sites,
as the one performed on this paper, which is specific for PBS-PT 4D
dose calculations from liver cases.
In summary, to understand the influence of a particular regis-
tration algorithm on the 4D dose calculation, the accuracy of differ-
ent DIR methods to estimate the GT results has been analysed.
Regarding field-specific geometric registration error, it has been
shown that all DIR methods underestimate motion amplitude in
the fVOI for all applied fields. This consequently resulted in anoverestimation of the calculated plan index of V95(CTV) for all
DIR algorithms in comparison to the GT for most of the 4D plan
configurations analysed. The performance of this study is of great
importance for the proton therapy community in general, and par-
ticularly for PBS-PT, due to its sensitivity to respiratory-induced
impacts. As well for passively scattered proton therapy, or even
conventional radiotherapy, where DIR is widely used for dose
distribution warping and accumulation, we believe that our out-
comes, especially on the DIR induced geometric error assessment,
still remain noteworthy [33,34].
Conclusion
The demonstrated dosimetric errors induced by different DIR
methods indicate the necessity to interpret individual 4D dose dis-
tributions for PBS-PT plans for liver cases with caution, and ideally
with an error bar. However, by adding fields to the treatment plan
and/or using motion mitigation techniques such as rescanning, the
impact of DIR motion estimation uncertainties on the 4D dose dis-
tributions could be reduced.
Fig. 5. DDVH band between investigated DIR and GT in the extended CTV (CTV + 1 cm) for all (a) single- vs. (b) three-field 4D plan configurations. Each individual plot gives
the information for all motion scenarios (A, B, and C). The boxplots give the statistics of the volume of extended CTV with absolute dose differences higher than 10 %, with
respect to DIR method used as input for the 4D dose calculation.
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